Research Analysts’ Recent Ratings Changes for Kymera Therapeutics (KYMR)

11 Dec 2025, 08:58 by Jessica Moore · The Cerbat Gem

A number of research firms have changed their ratings and price targets for Kymera Therapeutics (NASDAQ: KYMR):

12/11/2025 – Kymera Therapeutics had its “overweight” rating reaffirmed by analysts at Stephens.
12/11/2025 – Kymera Therapeutics had its price target raised by analysts at Mizuho from $81.00 to $120.00. They now have an “outperform” rating on the stock.
12/10/2025 – Kymera Therapeutics had its price target raised by analysts at JPMorgan Chase & Co. from $70.00 to $125.00. They now have an “overweight” rating on the stock.
12/9/2025 – Kymera Therapeutics had its price target raised by analysts at Jefferies Financial Group Inc. from $73.00 to $122.00. They now have a “buy” rating on the stock.
12/9/2025 – Kymera Therapeutics had its price target raised by analysts at Truist Financial Corporation from $80.00 to $116.00. They now have a “buy” rating on the stock.
12/9/2025 – Kymera Therapeutics had its price target raised by analysts at HC Wainwright from $84.00 to $134.00. They now have a “buy” rating on the stock.
12/9/2025 – Kymera Therapeutics had its price target raised by analysts at Oppenheimer Holdings, Inc. from $67.00 to $120.00. They now have an “outperform” rating on the stock.
12/9/2025 – Kymera Therapeutics had its price target raised by analysts at Morgan Stanley from $73.00 to $127.00. They now have an “overweight” rating on the stock.
12/9/2025 – Kymera Therapeutics had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $125.00 price target on the stock, up previously from $98.00.
12/9/2025 – Kymera Therapeutics had its price target raised by analysts at Citigroup Inc. from $80.00 to $110.00. They now have a “buy” rating on the stock.
12/9/2025 – Kymera Therapeutics had its price target raised by analysts at Wells Fargo & Company from $69.00 to $116.00. They now have an “overweight” rating on the stock.
12/9/2025 – Kymera Therapeutics had its price target raised by analysts at Barclays PLC from $70.00 to $119.00. They now have an “overweight” rating on the stock.
12/9/2025 – Kymera Therapeutics had its price target raised by analysts at Bank of America Corporation from $71.00 to $112.00. They now have a “buy” rating on the stock.
12/8/2025 – Kymera Therapeutics had its price target raised by analysts at Leerink Partners from $70.00 to $118.00. They now have an “outperform” rating on the stock.
12/8/2025 – Kymera Therapeutics was given a new $138.00 price target on by analysts at BTIG Research.
12/8/2025 – Kymera Therapeutics had its price target raised by analysts at BTIG Research from $75.00 to $138.00. They now have a “buy” rating on the stock.
12/8/2025 – Kymera Therapeutics was given a new $114.00 price target on by analysts at Stifel Nicolaus.
12/4/2025 – Kymera Therapeutics was upgraded by analysts at UBS Group AG to a “strong-buy” rating.
11/26/2025 – Kymera Therapeutics had its price target raised by analysts at Truist Financial Corporation from $68.00 to $80.00. They now have a “buy” rating on the stock.
11/26/2025 – Kymera Therapeutics was given a new $90.00 price target on by analysts at UBS Group AG. They now have a “buy” rating on the stock.
11/8/2025 – Kymera Therapeutics was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
11/5/2025 – Kymera Therapeutics had its price target raised by analysts at HC Wainwright from $70.00 to $84.00. They now have a “buy” rating on the stock.
11/5/2025 – Kymera Therapeutics had its price target raised by analysts at Barclays PLC from $60.00 to $70.00. They now have an “overweight” rating on the stock.
11/5/2025 – Kymera Therapeutics had its price target raised by analysts at Wells Fargo & Company from $53.00 to $69.00. They now have an “overweight” rating on the stock.
11/4/2025 – Kymera Therapeutics had its “overweight” rating reaffirmed by analysts at Morgan Stanley. They now have a $73.00 price target on the stock.
11/4/2025 – Kymera Therapeutics had its “buy” rating reaffirmed by analysts at Jefferies Financial Group Inc.. They now have a $73.00 price target on the stock.
11/4/2025 – Kymera Therapeutics had its “outperform” rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $67.00 price target on the stock.
11/3/2025 – Kymera Therapeutics is now covered by analysts at Guggenheim. They set a “buy” rating and a $90.00 price target on the stock.
11/3/2025 – Kymera Therapeutics is now covered by analysts at Guggenheim. They set a “buy” rating and a $90.00 price target on the stock.
10/24/2025 – Kymera Therapeutics had its price target raised by analysts at B. Riley from $60.00 to $80.00. They now have a “buy” rating on the stock.
10/22/2025 – Kymera Therapeutics had its price target raised by analysts at BTIG Research from $59.00 to $75.00. They now have a “buy” rating on the stock.
10/21/2025 – Kymera Therapeutics is now covered by analysts at Mizuho. They set an “outperform” rating and a $81.00 price target on the stock.
10/20/2025 – Kymera Therapeutics was upgraded by analysts at Mizuho to a “strong-buy” rating.
10/17/2025 – Kymera Therapeutics had its price target raised by analysts at Citigroup Inc. from $60.00 to $80.00. They now have a “buy” rating on the stock.

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, CFO Bruce N. Jacobs sold 79,220 shares of the company’s stock in a transaction that occurred on Wednesday, September 17th. The stock was sold at an average price of $50.00, for a total transaction of $3,961,000.00. Following the completion of the sale, the chief financial officer directly owned 227,409 shares of the company’s stock, valued at $11,370,450. This represents a 25.84% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jeffrey W. Albers sold 5,000 shares of the stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $89.76, for a total value of $448,800.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 361,217 shares of company stock valued at $25,140,500 over the last ninety days. 16.01% of the stock is currently owned by corporate insiders.

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.

Research Analysts’ Recent Ratings Changes for Kymera Therapeutics (KYMR)

Insider Buying and Selling at Kymera Therapeutics

Featured Articles